Navigation Links
Inovio Pharmaceuticals to Present at 13th Annual BIO CEO & Investor Conference
Date:2/8/2011

ty to successfully integrate Inovio and VGX Pharmaceuticals, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2009, our Form 10-Q for the nine months ended September 30, 2010, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

CONTACTS:Investors:

Bernie Hertel, Inovio Pharmaceuticals 858-410-3101 bhertel@inovio.comMedia:

Jeff Richardson, Richardson & Associates 805-491-8313 jeff@richardsonglobalpr.com(Logo:  http://photos.prnewswire.com/prnh/20110127/LA37605LOGO)


'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Results and Conduct Conference Call on Thursday, February 10, 2011
2. Vanda Pharmaceuticals to Announce Fourth Quarter 2010 Financial Results on February 10, 2011
3. Onyx Pharmaceuticals Receives Fast Track Designation for Carfilzomib; Company Initiates Rolling NDA Submission for Accelerated Approval
4. Cadence Pharmaceuticals Announces U.S. Launch and Availability of OFIRMEV™ (acetaminophen) Injection
5. Cempra Pharmaceuticals Profiles the Broad Spectrum and Potent Activity Profile of Solithromycin (CEM-101) at the 5th Annual PHEMCE Stakeholders Workshop and BARDA Industry Day
6. Takeda and Zinfandel Pharmaceuticals Sign Licensing Agreement for Alzheimers Disease Biomarker in Combination with Pioglitazone
7. Savient Pharmaceuticals Provides Business Update
8. Anthera Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
9. Anadys Pharmaceuticals Augments Management Team and Board of Directors
10. Isis Pharmaceuticals Adds Two New Drugs to Development Pipeline
11. Onyx Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 29, 2015 US-Australian drug discovery company, Novogen ... it is committed to progressing its ground-breaking technology platforms ... and to ensure the Company delivers the best value ... Iain Ross , said the Company currently had an ... programs, discovery programs and academic partnerships and initiatives, and ...
(Date:7/29/2015)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ) today announced ... Officer has resigned.  The Company has hired Andrew ... in December 2014, as full time interim CFO and ... Andy Ashworth began his employment today, ... transition.  Andy was the Company,s CFO from September 2011 ...
(Date:7/29/2015)... 29, 2015  AsureQuality and Ubiquitome have agreed ... applications in food and primary production sectors. The ... PCR device, the Freedom4. AsureQuality provides ... the supermarket shelf for producers, processors and Competent ... animal disease control and pest management and surveillance ...
(Date:7/29/2015)... , July 29, 2015 ... announced the addition of the "Global Biosimilars ... offering. The Global Biosimilars Market, 2015 ... the rapidly growing biosimilars market. With the blockbuster ... to minimize costs, biosimilars are being viewed as ...
Breaking Biology Technology:Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3
... Corporation (Nasdaq: DNDN ) today announced that management ... in San Francisco on Thursday, January 15, 2009 at 11:00 ... presentation will be accessible through the Investor Relations section of ... to listen to the live webcast, it will be archived ...
... CRANBURY, N.J., Jan. 8 Amicus Therapeutics (Nasdaq: ... J. Barer, Ph.D., to its Board of Directors. ... Officer of Celgene Corporation. As an industry veteran, ... and a reputation as a trusted and respected leader ...
... CAMBRIDGE, Mass. January 7, 2008 Researchers from Harvard ... for the first time, a repulsive quantum mechanical force that ... new nanotechnology applications. , The study, led by Federico Capasso, ... of Engineering and Applied Science (SEAS), will be published as ...
Cached Biology Technology:Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors 2Researchers measure elusive repulsive force from quantum fluctuations 2
(Date:7/31/2015)... juli 2015 Den 10. internationale konference om ... den 22. - 25. oktober i Shenzhen ... 10-års fødselsdag i år. Siden starten i 2006 er ... på ,omik,-feltet, og er en af de mest dynamiske, ... fokuserer på nylige gennembrud og fremskridt inden for ,omik,-forskning, ...
(Date:7/31/2015)... 31 de julio de 2015 BGI llevará a ... ) del 22 al 25 de octubre de 2015, ... La conferencia celebra su décimo aniversario este año. Desde ... una de las reuniones anuales más influyentes del mundo ... de las conferencias científicas más dinámicas, entusiastas y amenas. ...
(Date:7/31/2015)... China , 31 de julho de 2015 /PRNewswire/ ... (ICG-10, www.icg-10.org ) será realizada pela BGI de 22-25 ... . A conferência está celebrando seu ... em 2006, a ICG se tornou uma das reuniões ... um dos encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... Evolution Group participated in an international research that has resulted ... fly species. The study also includes new data on the ... sixty million years. The research, published in Nature, was ... over the world and consisted in the analysis of the ...
... Inc. and the Prostate Cancer Foundation today announced they ... Program (for Special Team Amplification of Research), an innovative ... heat in cancer therapy to treat prostate cancer, as ... is being launched for the first phase of research ...
... (November 15, 2007) -- In response to the need ... populations of the threatened staghorn coral, Diego Lirman, Ph.D., ... Rosenstiel School of Marine and Atmospheric Science (RSMAS) have ... of staghorn corals. The goals of the coral ...
Cached Biology News:Genome comparison of 12 fruit fly species 2Safeway Inc. and PCF to fund landmark prostate cancer research collaboration 2Safeway Inc. and PCF to fund landmark prostate cancer research collaboration 3Safeway Inc. and PCF to fund landmark prostate cancer research collaboration 4New south Florida nursery to focus on staghorn corals 2
... the ultimate in utility and flexibility press-to-seal ... the needs of the researcher. They are ... or as sheet material that can be ... isolators are autoclavable and non-cytotoxic and can ...
2,4-Dinitrophenyl hapten is conjugated to Human Serum Albumin (HSA) protein through lysine....
IC50: 3 ng/ml · Limit of detection: 0.5 ng/ml...
Antibodies were affinity purified using epitopes specific to PPP1CC immobilized on solid support....
Biology Products: